Matches in SemOpenAlex for { <https://semopenalex.org/work/W109015887> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W109015887 endingPage "52" @default.
- W109015887 startingPage "949" @default.
- W109015887 abstract "This study was purposed to investigate the effects of high-dose methotrexate (HD-MTX)-CF + VDT protocol on pediatric acute lymphoblastic leukemia (ALL) by means of retrospective analysis. MTX plasma concentration was dynamically detected and evaluated so as to avoid or reduce the side effects of HD-MTX, and adjust the time and dosage of calcium folinate (CF) or carry out the plasma exchange as occasion requires. Totally 180 cases of ALL were enrolled in this study, and received 380 administration of HD-MTX-CF + VDT protocol, including 122 patients with induction therapy as well as 58 cases during maintenance therapy, among which 68 cases were defined as low risk, 80 cases as middle risk and 32 cases as high risk. 2.0 g/m(2) MTX, 3.0 g/m(2) MTX, and 5.0 g/m(2) MTX were individually used according to low risk, middle risk or T immunohistochemical expression. The results indicated that 36.3% cases showed the side-effects of HD-MTX including mucocutaneous lesions, gastrointestinal reaction, hepatic dysfunction, renal damage, fever, myelosuppression, cardiotoxicity, infection and allergic response. All of these side effects were reversible through treatment. The elimination delay of MTX occurred in 110 cases, out of which 3 cases got MTX concentration > 10 µmol/L at 24 hours, 50 cases > 1.0 µmol/L at 44 hours, the remaining 57 cases > 0.1 µmol/L at 68 hours. CF dosage was adjusted according to the concentration of MTX until it was less than 0.1 µmol/L. 1 case had renal interstitial inflammation and acute renal failure, but finally he was cured. No patients received plasma exchange or died. It is concluded that the extramedullary leukemia control protocol, in which MTX is main drug, is effective therapy for obtaining long-term remission and event-free survival rate in ALL patients, but the side effects and risks increase along with the increase of MTX dose. The metabolic level of HD-MTX has found to be obvious individual, so the dynamic monitoring of MTX concentration in plasma and administration of proper dosage of CF are important factors for HD-MTX protocol application in ALL patients." @default.
- W109015887 created "2016-06-24" @default.
- W109015887 creator A5028973630 @default.
- W109015887 creator A5029181387 @default.
- W109015887 creator A5033020983 @default.
- W109015887 creator A5061084605 @default.
- W109015887 creator A5075158998 @default.
- W109015887 date "2011-08-01" @default.
- W109015887 modified "2023-09-25" @default.
- W109015887 title "[Efficacy, side effects and blood concentration monitoring of high-dose methotrexate in treatment of 180 children with acute lymphoblastic leukemia]." @default.
- W109015887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21867621" @default.
- W109015887 hasPublicationYear "2011" @default.
- W109015887 type Work @default.
- W109015887 sameAs 109015887 @default.
- W109015887 citedByCount "3" @default.
- W109015887 countsByYear W1090158872017 @default.
- W109015887 countsByYear W1090158872022 @default.
- W109015887 crossrefType "journal-article" @default.
- W109015887 hasAuthorship W109015887A5028973630 @default.
- W109015887 hasAuthorship W109015887A5029181387 @default.
- W109015887 hasAuthorship W109015887A5033020983 @default.
- W109015887 hasAuthorship W109015887A5061084605 @default.
- W109015887 hasAuthorship W109015887A5075158998 @default.
- W109015887 hasConcept C126322002 @default.
- W109015887 hasConcept C156662089 @default.
- W109015887 hasConcept C199360897 @default.
- W109015887 hasConcept C2778233292 @default.
- W109015887 hasConcept C2778461978 @default.
- W109015887 hasConcept C2779134260 @default.
- W109015887 hasConcept C2781059491 @default.
- W109015887 hasConcept C29730261 @default.
- W109015887 hasConcept C3454156 @default.
- W109015887 hasConcept C41008148 @default.
- W109015887 hasConcept C71924100 @default.
- W109015887 hasConcept C90924648 @default.
- W109015887 hasConcept C98274493 @default.
- W109015887 hasConceptScore W109015887C126322002 @default.
- W109015887 hasConceptScore W109015887C156662089 @default.
- W109015887 hasConceptScore W109015887C199360897 @default.
- W109015887 hasConceptScore W109015887C2778233292 @default.
- W109015887 hasConceptScore W109015887C2778461978 @default.
- W109015887 hasConceptScore W109015887C2779134260 @default.
- W109015887 hasConceptScore W109015887C2781059491 @default.
- W109015887 hasConceptScore W109015887C29730261 @default.
- W109015887 hasConceptScore W109015887C3454156 @default.
- W109015887 hasConceptScore W109015887C41008148 @default.
- W109015887 hasConceptScore W109015887C71924100 @default.
- W109015887 hasConceptScore W109015887C90924648 @default.
- W109015887 hasConceptScore W109015887C98274493 @default.
- W109015887 hasIssue "4" @default.
- W109015887 hasLocation W1090158871 @default.
- W109015887 hasOpenAccess W109015887 @default.
- W109015887 hasPrimaryLocation W1090158871 @default.
- W109015887 hasRelatedWork W109015887 @default.
- W109015887 hasRelatedWork W1963845345 @default.
- W109015887 hasRelatedWork W1967234838 @default.
- W109015887 hasRelatedWork W2058269597 @default.
- W109015887 hasRelatedWork W2412338183 @default.
- W109015887 hasRelatedWork W2413304296 @default.
- W109015887 hasRelatedWork W2759959190 @default.
- W109015887 hasRelatedWork W2803649320 @default.
- W109015887 hasRelatedWork W2899084033 @default.
- W109015887 hasRelatedWork W4281784531 @default.
- W109015887 hasVolume "19" @default.
- W109015887 isParatext "false" @default.
- W109015887 isRetracted "false" @default.
- W109015887 magId "109015887" @default.
- W109015887 workType "article" @default.